Palisade Bio, Inc.

Equities

SNCA

US6963894026

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:01 2024-05-03 pm EDT			5-day change	1st Jan Change
7.74 ^USD	+6.17%		+27.93%	-12.54%

May. 01	Wall Street Set to Open Lower Ahead of Fed Rate Decision; Private Employment Figures Top Forecasts	MT
May. 01	Palisade Bio?s Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide	CI

Palisade Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022

August 15, 2022 at 08:24 am EDT

Palisade Bio, Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported net loss was USD 2.34 million compared to USD 31.75 million a year ago. Basic loss per share from continuing operations was USD 6 compared to USD 179.5 a year ago. Diluted loss per share from continuing operations was USD 6 compared to USD 205 a year ago.
For the six months, net loss was USD 6.55 million compared to USD 35.78 million a year ago. Basic loss per share from continuing operations was USD 18 compared to USD 308.5 a year ago. Diluted loss per share from continuing operations was USD 18 compared to USD 348 a year ago.

Latest news about Palisade Bio, Inc.

Wall Street Set to Open Lower Ahead of Fed Rate Decision; Private Employment Figures Top Forecasts	May. 01	MT
Palisade Bio?s Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide	May. 01	CI
Palisade Bio, Inc. announced that it expects to receive $3.999996 million in funding	Apr. 30	CI
Palisade Bio Collaborating With Strand Life Sciences on Ulcerative Colitis Therapy	Apr. 23	MT
Palisade Bio, Inc. Enters into Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine Approach	Apr. 23	CI
Sector Update: Health Care Stocks Edge Up Tuesday Afternoon	Apr. 16	MT
Palisade Bio Shows Bioactivation of PALI-2108 in Study; Shares Rise	Apr. 16	MT
Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients? Stool	Apr. 16	CI
North American Morning Briefing : Stocks Seen -2-	Apr. 02	DJ
Palisade Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26	CI
Palisade Bio, Inc. Announces Resignation of Mary Ann Gray as Member of the Board	Mar. 06	CI
Palisade Bio Names Donald Williams as Chairman	Feb. 13	MT
Palisade Bio, Inc. Announces Advisory Board Appointments	Feb. 08	CI
Sector Update: Health Care Stocks Stronger Late Afternoon	Jan. 29	MT
Sector Update: Health Care Stocks Advance Monday Afternoon	Jan. 29	MT
Top Midday Gainers	Jan. 29	MT
Palisade Bio's Shares Climb Following Preclinical Data on Ulcerative Colitis Drug Candidate	Jan. 29	MT
Palisade Bio Says Giiant Pharma Receives Second Milestone Payment for PALI-2108 Development	Dec. 28	MT
North American Morning Briefing : Stocks Futures -2-	Nov. 20	DJ
Maxim Upgrades Palisade Bio to Buy From Hold, Price Target is $1.50	Nov. 17	MT
North American Morning Briefing : Investors Weigh -2-	Nov. 10	DJ
Palisade Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Palisade Bio, Inc. Announces the Appointment of Mitchell Jones, M.D., Ph.D., as Chief Medical Officer	23-09-11	CI
Palisade Bio, Inc. Appoints Mitchell Jones as Chief Medical Officer	23-09-11	CI
Sector Update: Health Care Stocks Advancing Late Thursday Afternoon	23-09-07	MT

Chart Palisade Bio, Inc.

Duration

Period

More charts

Company Profile

Palisade Bio, Inc. is a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal diseases. It is engaged in advancing a PALI-2108 for the treatment of IBD, including UC and CD and are researching PALI-1908. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract. UC primarily affects the colon and the rectum. CD can affect any part of the gastrointestinal tract, from the mouth to the anus. PALI-2108 is a prodrug PDE4 inhibitor that operates through a mechanism within colon tissues, targeting the key enzyme phosphodiesterase-4 (PDE4). This enzyme is pivotal in cAMP hydrolysis, and by inhibiting PDE4, intracellular cAMP levels are elevated. This elevation leads to the downregulation of inflammatory cytokines and a reduction in the expression of cell adhesion molecules. By modulating these processes, PALI-2108 prevents the local infiltration and activation of inflammatory cells in the colon tissues.

Sector

Biotechnology & Medical Research

Calendar

2024-05-09 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

7.74 USD

Average target price

33.75 USD

Spread / Average Target

+336.05%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
PALISADE BIO, INC.	-12.54%	6.59M
MODERNA, INC.	+25.69%	47.9B
LONZA GROUP AG	+47.41%	41.42B
IQVIA HOLDINGS INC.	-3.46%	40.7B
CELLTRION, INC.	-6.20%	28.92B
ICON PUBLIC LIMITED COMPANY	+9.17%	25.55B
ALNYLAM PHARMACEUTICALS, INC.	-20.42%	19.27B
BIO-TECHNE CORPORATION	+0.17%	12.15B
MEDPACE HOLDINGS, INC.	+28.07%	12.14B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.24%	11.99B

Other Biotechnology & Medical Research